625445-85-4

Basic information

• Product Name: 1-CYCLOPENTYL-3-(2,4-DIMETHOXYPHENYL)PROPAN-1-ONE
• Synonyms: 1-CYCLOPENTYL-3-(2,4-DIMETHOXYPHENYL)PROPAN-1-ONE
• CAS NO: 625445-85-4
• Molecular Formula: C₁₆H₂₂O₃
• Molecular Weight: 262.34
• Mol File: 625445-85-4.mol

Chemical Properties

• Boiling Point: 382.763°C at 760 mmHg
• Flash Point: 176.764°C
• Appearance: /
• Density: 1.07g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.522
• CAS DataBase Reference: 1-CYCLOPENTYL-3-(2,4-DIMETHOXYPHENYL)PROPAN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-CYCLOPENTYL-3-(2,4-DIMETHOXYPHENYL)PROPAN-1-ONE(625445-85-4)
• EPA Substance Registry System: 1-CYCLOPENTYL-3-(2,4-DIMETHOXYPHENYL)PROPAN-1-ONE(625445-85-4)

Safety Data

• Hazardous Substances Data: 625445-85-4(Hazardous Substances Data)

Usage

Classification

Ketone

Explanation

A ketone is a type of organic compound characterized by the presence of a carbonyl group (C=O) bonded to two other carbon atoms.

Explanation

The compound has a five-membered cyclopentyl ring and a phenyl group with two methoxy groups (-OCH3) attached to the 2nd and 4th carbon atoms.

Explanation

Due to its unique structure, 1-CYCLOPENTYL-3-(2,4-DIMETHOXYPHENYL)PROPAN-1-ONE is used as an intermediate in the synthesis of various organic compounds. It also has potential applications in the development of pharmaceuticals and fragrances.

Explanation

The compound may exhibit biological activities that could be relevant for the development of new drugs or therapies, making it an interesting subject for medicinal chemistry research.

Explanation

The exact properties and uses of 1-CYCLOPENTYL-3-(2,4-DIMETHOXYPHENYL)PROPAN-1-ONE may change depending on how it is used or the specific context in which it is applied.

Structural Features

Cyclopentyl ring and 2,4-dimethoxyphenyl group

Applications

Organic synthesis, pharmaceutical and fragrance industries

Biological Activities

Potential interest for medicinal chemistry research

Property Variability

Depends on specific application and context

InChI:InChI=1/C16H22O3/c1-18-14-9-7-13(16(11-14)19-2)8-10-15(17)12-5-3-4-6-12/h7,9,11-12H,3-6,8,10H2,1-2H3

Upstream product

• 6004-60-0 1-cyclopentylethanone 
• 613-45-6 2,4-Dimethoxybenzaldehyde 

Downstream Products

• 625445-86-5 6-[2-(2,4-dimethoxy-phenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione 

Relevant articles and documents

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same

The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).